Loading patent…
OwnerSylvain Arnould, Patrick Chames +3inventors
InventorsSylvain Arnould, Patrick Chames, Andre Choulika, Jean-Charles Epinat, Emmanuel Lacroix
Estimating the term…
This patent application relates to hybrid and/or single-chain rare-cutting endonucleases, called meganucleases, which recognized and cleave a specific nucleotide sequence, to polynucleotide sequences encoding for said rare-cutting endonucleases, to a vector comprising one of said polynucleotide sequences, to a cell or animal non-human comprising one of said polynucleotide sequences or said rare-cutting endonucleases, to a process for producing one of said rare-cutting endonucleases and any use of the disclosed products and methods. More particularly, this invention contemplates any use of such rare-cutting endonuclease for genetic engineering and gene therapy.
A hybrid meganuclease comprising a first domain and a second domain in the orientation N-terminal toward C-terminal, said first and second domains being derived from two different initial dodecapeptide meganueleases and wherein said hybrid meganuclease is capable of causing DNA cleavage.
A hybrid meganuclease comprising a first and a second domains in the orientation N-terminal toward C-terminal, wherein each domain are derived from the same di-dodecapeptide meganuclease and said first domain is derived from the C-terminal domain and said second domain is derived from the N-terminal domain and wherein said hybrid meganuclease is capable of causing DNA cleavage.
A single-chain meganuclease comprising a first and a second domain in the orientation N-terminal toward C-terminal, wherein said first and second domains are derived from the same mono-dodecapeptide meganuclease and wherein said single-chain meganuclease is capable of causing DNA cleavage.
Polynucleotide according to claim 28, wherein said site comprises two half-sites of the initial dodecapeptide meganucease.
30-32. (canceled)
Dependencies are inferred from the claim text.